Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633813 · ClinicalTrials.gov registry record · Phase 3
BE Study of Naftifine HCL
A Phase 3 study of Tinea Pedis, sponsored by Genzum Life Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 693
- Enrollment target
- 14
- Study locations
NCT02633813 is a Phase 3 study of Tinea Pedis that has completed, run by Genzum Life Sciences. The registered enrollment target is 693 participants, above the 250-participant average among 9 other Tinea Pedis trials with a reported enrollment target (177% higher). The trial reports 14 study locations across 5 states.
The verdict
NCT02633813, a Phase 3 study of Tinea Pedis, has completed, sponsored by Genzum Life Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 693 participants
- Enrollment target
- 14
- Study locations
Study Summary
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 + 2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at the end of week 6 + 4 days).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naftifine hydrochloride 2%
- DRUG Naftin® 2% (Naftifine hydrochloride 2%)
Study Locations (14)
Florida
- Moore Clinical Research Inc - Brandon
- Savin Medical Group Research - Miami
- International Dermatology Research, Inc, - Miami
- FXM Research Corp - Miami
- FXM Research Miramar - Miramar
- South Tampa, MOORE Clinical Research, Inc. - Tampa
- North Tampa MOORE Clinical Research, Inc. - Tampa
Texas
- Bellaire Dermatology Associates - Bellaire
- Research Across America - Dallas
- Family Practise - Mesquite
- Research Across America - Plano
Missouri
- Medi Search - Saint Joseph
San Cristóbal
- Instituto Dermatológico y Cirugía de Piel - Santo Domingo
Santo Domingo Province
- Instituto Dermatológico - Barrio Maria Auxiliadora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 693 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633813
The ClinicalTrials.gov registry entry for NCT02633813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 693 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 250-participant average among 9 other Tinea Pedis trials with a reported enrollment target (177% higher). The listed sponsor is Genzum Life Sciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tinea Pedis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02633813 reports 14 study locations spanning 5 distinct geographic areas - top geographies include Florida, Texas, Missouri.
Frequently Asked Questions
What is clinical trial NCT02633813 about?
NCT02633813 is a clinical study titled "BE Study of Naftifine HCL". The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the ...
What is the current status of trial NCT02633813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 693 participants. The study started on 2015-03. Estimated completion is 2015-12.
What conditions does trial NCT02633813 study?
This clinical trial studies the following conditions: Tinea Pedis.
What interventions are being tested in trial NCT02633813?
The interventions under investigation include: Placebo (DRUG), Naftifine hydrochloride 2% (DRUG), Naftin® 2% (Naftifine hydrochloride 2%) (DRUG).
Who is sponsoring clinical trial NCT02633813?
This trial is sponsored by Genzum Life Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02633813 being conducted?
This trial has 14 study locations across Florida, Missouri, Texas, San Cristóbal, Santo Domingo Province. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
COMPLETED · Phase 3
-
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
COMPLETED · Phase 3
-
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
COMPLETED · Phase 3
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.